Revolution Medicines' Daraxonrasib Doubles Survival in Pancreatic Cancer Trial
Revolution Medicines announced Phase 3 results showing its experimental daily pill daraxonrasib nearly doubled median survival in advanced pancreatic adenocarcinoma patients — 13.2 months versus 6.7 months on standard chemotherapy. A pancreatic cancer expert cited by STAT News said the data could 'open up a new era' of treatment. The company plans to seek FDA approval based on the results.
Реклама: Article Inline